(Q53877712)

21 May 2018

title

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. (English)

1 reference

21 May 2018

1 reference

4

John Mascola

1 reference

21 May 2018

6

Joseph Sodroski

1 reference

21 May 2018

7

Richard Wyatt

1 reference

21 May 2018

Mark K. Louder

3

object named as

Mark Louder

1 reference

21 May 2018

author name string

Christoph Grundner

1

1 reference

21 May 2018

Yuxing Li

2

1 reference

21 May 2018

Xinzhen Yang

5

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 January 2005

1 reference

21 May 2018

published in

Virology

1 reference

21 May 2018

volume

331

1 reference

21 May 2018

issue

1

1 reference

21 May 2018

page(s)

33-46

1 reference

21 May 2018

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Energetics of the HIV gp120-CD4 binding reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

HIV-1 antibody--debris or virion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long‐Term‐Nonprogressive Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Antibody-Dependent Enhancement of Virus Infection and Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.022

7 January 2021

10.1016/J.VIROL.2004.09.022

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018